NMTC NEUROONE MEDICAL TECHNOLOGIES Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1500198 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY42.8%
TTM net income YoY-39.5%
TTM EPS YoY-20.9%
Revenue 3-yr CAGR94.9%
Net income 3-yr CAGR—
Margins
Gross margin55.6%
Operating margin-83.4%
Net margin-78.6%
FCF margin-75.6%
EBITDA margin-81.0%
Returns
ROE-124.7%
ROA-87.6%
ROIC (approx.)-671.9%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $9.10M | $3.45M | $1.95M | $171,169 | $178,146 |
| Cost of revenue | $3.96M | $2.37M | $1.50M | $241,963 | $275,895 |
| Gross profit | $5.14M | $1.08M | $456,517 | -$70,794 | -$97,749 |
| R&D expense | $4.98M | $5.07M | $6.94M | $4.93M | $3.93M |
| SG&A expense | $7.38M | $7.90M | $6.93M | $6.98M | $6.26M |
| Operating income | -$4.23M | -$11.89M | -$11.96M | -$10.03M | -$10.22M |
| Interest expense | — | — | — | — | $3,053 |
| Pretax income | -$3.61M | -$12.32M | -$11.86M | -$10.00M | — |
| Income tax | — | — | — | — | -$271,122 |
| Net income | -$3.61M | -$12.32M | -$11.86M | -$10.00M | -$9.95M |
| EBITDA | -$3.96M | -$11.64M | -$11.76M | -$9.91M | -$10.14M |
| EPS (basic) | -0.09 | -0.46 | -0.65 | -0.63 | -0.93 |
| EPS (diluted) | -0.09 | -0.46 | -0.65 | -0.63 | -0.93 |
| Weighted avg. shares (diluted) | 40.15M | 26.76M | 18.12M | 16.00M | 10.70M |
| Banking | |||||
| Net interest income | — | — | — | — | -$3,053 |
| Balance sheet | |||||
| Cash & equivalents | $6.57M | $1.46M | $5.32M | $8.16M | $6.90M |
| Short-term investments | — | — | — | $2.98M | — |
| Receivables | $1.26M | $176,636 | — | $33,237 | $48,336 |
| Inventory | $2.23M | $2.64M | $1.73M | $704,538 | $98,287 |
| Current assets | $10.23M | $4.63M | $7.31M | $12.18M | $7.29M |
| PP&E, net | $259,222 | $416,843 | $525,753 | $353,599 | $223,329 |
| Intangibles | $44,946 | $67,262 | $89,577 | $111,892 | $134,207 |
| Total assets | $10.79M | $5.37M | $8.10M | $12.82M | $7.94M |
| Current liabilities | $2.30M | $2.21M | $1.79M | $3.10M | $1.18M |
| Short-term debt | — | — | $129,116 | — | — |
| Long-term debt | — | — | $55,284 | $119,556 | $202,895 |
| Total debt | — | — | $184,400 | $119,556 | $202,895 |
| Total liabilities | $3.71M | $4.55M | $1.85M | $3.22M | $1.38M |
| Shareholders' equity | $7.07M | $822,013 | $6.25M | $9.60M | $6.55M |
| Net debt | — | — | -$5.14M | -$8.04M | -$6.70M |
| Shares outstanding | 8.33M | 30.82M | 23.93M | 16.22M | 12.01M |
| Cash flow statement | |||||
| Operating cash flow | -$2.84M | -$11.01M | -$12.89M | -$7.52M | -$8.60M |
| Capital expenditure | $81,742 | $120,197 | $384,117 | $275,226 | $67,079 |
| Free cash flow | -$2.92M | -$11.13M | -$13.27M | -$7.79M | -$8.67M |
| Investing cash flow | -$81,742 | -$120,197 | $2.65M | -$3.24M | -$67,079 |
| Financing cash flow | $8.03M | $7.27M | $7.40M | $12.02M | $11.53M |
| Depreciation & amortization | $261,679 | $246,791 | $199,266 | $118,620 | $80,748 |
| Stock-based compensation | $1.26M | $1.34M | $1.11M | $947,212 | $1.79M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.